Skip to main content
. 2020 Oct 15;45(3):461–471. doi: 10.1080/10790268.2020.1829416

Table 6. Distribution of antibiotics used to treat UTI during follow-up.

  NIDRR definition (N = 10) CMS definition (N = 25) Togan definition (N = 20) EAU definition (N = 24) Burgdörfer definition (N = 21) Any mention of the term UTI (N = 33) Any of the 6 definitions (N = 42)
  N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Any antibiotic 9 (90.0%) 21 (84.0%) 19 (95.0%) 20 (83.3%) 17 (81.0%) 32 (97.0%) 38 (90.5%)
No antibiotic 1 (10.0%) 4 (16.0%) 1 (5.0%) 4 (16.7%) 4 (19.1%) 1 (3.0%) 4 (9.5%)
Monotherapy 3 (30.0%) 7 (28.0%) 6 (30.0%) 9 (37.5%) 7 (33.3%) 11 (33.3%) 14 (33.3%)
Polypharmacy 6 (60.0%) 14 (56.0%) 13 (65.0%) 11 (45.8%) 10 (47.6%) 21 (63.6%) 24 (57.1%)
Specific antibiotic              
Carbapenem 2 (20.0%) 2 (8.0%) 2 (10.0%) 2 (8.3%) 2 (9.5%) 5 (15.2%) 5 (11.9%)
Cephalosporin 1 (10.0%) 6 (24.0%) 6 (30.0%) 4 (16.7%) 3 (14.3%) 6 (18.2%) 8 (19.1%)
Ciprofloxacin 7 (70.0%) 16 (64.0%) 14 (70.0%) 15 (62.5%) 14 (66.7%) 21 (63.6%) 23 (54.8%)
Nitrofurantoin 2 (20.0%) 9 (36.0%) 8 (40.0%) 6 (25.0%) 5 (23.8%) 11 (33.3%) 14 (33.3%)
Aminoglycoside 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%) 1 (2.4%)
Clindamycin 0 (0.0%) 1 (4.0%) 0 (0.0%) 1 (4.2%) 1 (4.8%) 1 (3.0%) 1 (2.4%)
Colistin 1 (10.0%) 1 (4.0%) 1 (5.0%) 1 (4.2%) 1 (4.8%) 1 (3.0%) 1 (2.4%)
Sulfonamide 0 (0.0%) 1 (4.0%) 1 (5.0%) 1 (4.2%) 1 (4.8%) 4 (12.1%) 4 (9.5%)
Vancomycin 0 (0.0%) 1 (4.0%) 1 (5.0%) 1 (4.2%) 1 (4.8%) 2 (6.1%) 2 (4.8%)
Penicillins and penicillin combinations 4 (40.0%) 6 (24.0%) 6 (30.0%) 4 (16.7%) 4 (19.1%) 7 (21.2%) 9 (21.4%)
Other antibiotic* 3 (30.0%) 4 (16.0%) 4 (20.0%) 5 (20.8%) 4 (19.1%) 9 (27.3%) 10 (23.8%)

Abbreviation: CMS, Centers for Medicare and Medicaid Services; EAU, European Association of Urology; NIDRR, National Institute on Disability and Rehabilitation Research; UTI, urinary tract infection.

Note: Percentages based on subgroup of patients who experienced UTI during follow-up (n = 42).

*Other antibiotics include fosfomycin, fusidic acid, metronidazole, and rifampicin.